Omnicell (OMCL) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMCL, but not buy additional shares or sell existing shares.
View OMCL analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1-year price targets for Omnicell's stock. Their OMCL share price forecasts range from $39.00 to $75.00. On average, they anticipate the company's stock price to reach $64.38 in the next year. This suggests a possible upside of 45.0% from the stock's current price.
View analysts price targets for OMCL or view top-rated stocks among Wall Street analysts.

Omnicell's stock was trading at $50.42 at the start of the year. Since then, OMCL shares have decreased by 11.9% and is now trading at $44.41.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our OMCL earnings forecast.

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Tuesday, August, 1st. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.30. The business had revenue of $298.97 million for the quarter, compared to the consensus estimate of $285.25 million. Omnicell had a positive trailing twelve-month return on equity of 4.47% and a negative net margin of 1.88%.

ETFs with the largest weight of Omnicell (NASDAQ:OMCL) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ).iShares U.S. Medical Devices ETF (IHI).

Omnicell updated its FY23 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $1.75-$2.00 for the period, compared to the consensus estimate of $1.68. The company issued revenue guidance of $1.16-$1.20 billion, compared to the consensus revenue estimate of $1.18 billion.

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OMCL stock can currently be purchased for approximately $44.41.

Omnicell (NASDAQ:OMCL) has a market capitalization of $2.01 billion and generates $1.30 billion in revenue each year. The company earns $5.65 million in net income (profit) each year or ($0.52) on an earnings per share basis.

The company employs 4,230 workers across the globe.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (877) 415-9990, via email at ir@omnicell.com, or via fax at 847-596-3402.